Literature DB >> 33443087

MAP3K8 Regulates Cox-2-Mediated Prostaglandin E2 Production in the Lung and Suppresses Pulmonary Inflammation and Fibrosis.

Markella Zannikou1, Ilianna Barbayianni1, Dionysios Fanidis1, Theodora Grigorakaki1, Evlalia Vlachopoulou1, Dimitris Konstantopoulos2, Maria Fousteri2, Ioanna Nikitopoulou3, Anastasia Kotanidou3,4, Eleanna Kaffe1, Vassilis Aidinis5.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by exuberant deposition of extracellular matrix components, leading to the deterioration of lung architecture and respiratory functions. Profibrotic mechanisms are controlled by multiple regulatory molecules, including MAPKs, in turn regulated by multiple phosphorylation cascades. MAP3K8 is an MAPK kinase kinase suggested to pleiotropically regulate multiple pathogenic pathways in the context of inflammation and cancer; however, a possible role in the pathogenesis of IPF has not been investigated. In this report, MAP3K8 mRNA levels were found decreased in the lungs of IPF patients and of mice upon bleomycin-induced pulmonary fibrosis. Ubiquitous genetic deletion of Map3k8 in mice exacerbated the modeled disease, whereas bone marrow transfer experiments indicated that although MAP3K8 regulatory functions are active in both hematopoietic and nonhematopoietic cells, Map3k8 in hematopoietic cells has a more dominant role. Macrophage-specific deletion of Map3k8 was further found to be sufficient for disease exacerbation thus confirming a major role for macrophages in pulmonary fibrotic responses and suggesting a main role for Map3k8 in the homeostasis of their effector functions in the lung. Map3k8 deficiency was further shown to be associated with decreased Cox-2 expression, followed by a decrease in PGE2 production in the lung; accordingly, exogenous administration of PGE2 reduced inflammation and reversed the exacerbated fibrotic profile of Map3k8 -/- mice. Therefore, MAP3K8 has a central role in the regulation of inflammatory responses and Cox-2-mediated PGE2 production in the lung, and the attenuation of its expression is integral to pulmonary fibrosis development.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33443087     DOI: 10.4049/jimmunol.2000862

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Secretome of Mesenchymal Stem Cells from Consecutive Hypoxic Cultures Promotes Resolution of Lung Inflammation by Reprogramming Anti-Inflammatory Macrophages.

Authors:  Zhihong Xu; Lulu Lin; Yuxuan Fan; Céline Huselstein; Natalia De Isla; Xiaohua He; Yun Chen; Yinping Li
Journal:  Int J Mol Sci       Date:  2022-04-14       Impact factor: 6.208

2.  Fibromine is a multi-omics database and mining tool for target discovery in pulmonary fibrosis.

Authors:  Dionysios Fanidis; Panagiotis Moulos; Vassilis Aidinis
Journal:  Sci Rep       Date:  2021-11-05       Impact factor: 4.379

Review 3.  Extracellular Lipids in the Lung and Their Role in Pulmonary Fibrosis.

Authors:  Olivier Burgy; Sabrina Loriod; Guillaume Beltramo; Philippe Bonniaud
Journal:  Cells       Date:  2022-04-03       Impact factor: 6.600

4.  Aspirin Ameliorates Pancreatic Inflammation and Fibrosis by Inhibiting COX-2 Expression in Experimental Chronic Pancreatitis.

Authors:  Xiao-Fan Xu; Jian-Wei Fan; Jia-Qi Xin; Nan Wu; He Gao; Li-Fang Duan; Wen-Bin Zou; Hong Zhang; Zhao-Shen Li
Journal:  J Inflamm Res       Date:  2022-08-19

5.  Recognition of driver genes with potential prognostic implications in lung adenocarcinoma based on H3K79me2.

Authors:  Lu-Qiang Zhang; Hao Yang; Jun-Jie Liu; Li-Rong Zhang; Yu-Duo Hao; Jun-Mei Guo; Hao Lin
Journal:  Comput Struct Biotechnol J       Date:  2022-10-07       Impact factor: 6.155

6.  Influenza-induced Tpl2 expression within alveolar epithelial cells is dispensable for host viral control and anti-viral immunity.

Authors:  Kara D Wyatt; Demba Sarr; Kaori Sakamoto; Wendy T Watford
Journal:  PLoS One       Date:  2022-01-20       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.